No Data
No Data
Piper Sandler Maintains Cytek Biosciences(CTKB.US) With Buy Rating, Cuts Target Price to $8.25
In the Wake of Cytek Biosciences, Inc.'s (NASDAQ:CTKB) Latest US$84m Market Cap Drop, Institutional Owners May Be Forced to Take Severe Actions
Cytek Biosciences to Participate in the Piper Sandler 36th Annual Healthcare Conference
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Morgan Stanley Maintains Cytek Biosciences(CTKB.US) With Hold Rating, Maintains Target Price $9
Cautious Hold on Cytek Biosciences Amid Recovery and Growth Opportunities
No Data